Description

Clinical Evidence

• A 2015 Cell Metabolism study found that MOTS-c improves glucose homeostasis and reduces obesity-induced insulin resistance in mice.
• Researchers noted that MOTS-c activates AMPK, a master regulator of energy balance, mimicking the effects of exercise and caloric restriction.
• In aged mice, MOTS-c treatment led to increased physical endurance and improved mitochondrial respiration.
• Emerging data suggest roles in cognitive health and longevity, positioning MOTS-c as a key candidate in geroscience research.
Note: MOTS-c is unique among peptides due to its mitochondrial origin, giving it direct influence over energy balance and cellular resilience.

Potential Side Effects

Based on available preclinical studies, MOTS-c appears well tolerated. However, research is ongoing. Potential effects in lab models may include:
• Mild fatigue (rare, dose-dependent)
• Transient changes in appetite or blood glucose
• Unknown effects with long-term or supraphysiological dosing
No major adverse effects have been reported in animal studies to date, but further investigation is warranted.

Disclaimer

This peptide is for research use only. It is not approved for human or veterinary use. All benefits and safety data are derived from preclinical studies and early-stage research. This product should be used by trained professionals in a controlled laboratory setting.